In an interview, Bijan Almassian, president and CEO of CaroGen, a Farmington-based bioscience company, talks about developing a hepatitis B virus (HBV) immunotherapy, using replication-proficient virus-like vesicles (VLVs) technology.

 

CaroGen is also developing a vaccine against colorectal cancer.